Full Spectrum Infrasonic Stethoscope for Screening Heart, Carotid Artery, and Lung Related Diseases Allow physicians to screen heart, carotid artery, and lung related diseases at an early stage using full spectrum phonocardiography NASA Langley Research Center has developed an infrasonic stethoscope that detects a broader range of physiological conditions than conventional stethoscope, use of which has declined mainly due to availability of other advance technologies such as the echocardiogram. The echocardiograms can be complex, costly and require the need of a specialist for correct interpretation. Further, it is estimated that more than 85% population of the world does not have access to advanced diagnostic tools such as echocardiogram and CT scans. This scope provides additional data to physicians by monitoring signals across full frequency bandwidths that include cardiac, carotid artery, and respiration activities something that is not available in conventional stethoscopes.

Microphones and stethoscopes are regularly used by physicians to detect sounds when monitoring physiological conditions. These monitors are coupled directly to a person's body and measure in certain bandwidths either by listening or by recording the signals. The physiological processes such as respiration and cardiac activity are reflected in a different frequency bandwidth from 0.01 Hz to 500 Hz. This technology can monitor physiological conditions in the entire bandwidth range. Signals can also be wirelessly transmitted, using Bluetooth, to other recording devices at any other location. Benefits Can record heart, carotid artery, and lung sounds that cant be monitored by using a traditional stethoscope Measures systolic and diastolic time intervals Inexpensive alternative for screening of heart, carotid artery, and lung related diseases Provides real time fetal heart monitoring Applications Cardiac and respiratory patient monitoring Emergency use by First Responders Fetal heart monitoring Spirometry Other medical uses where simultaneous respiratory and cardiac monitoring is critical

Sprowtt Launch Pad Inc. was founded in 2019 as a subsidiary of Sprowtt Inc. Sprowtt, the parent company established in 2012, is a financial technology (FinTech) company that specializes in creating capital formation and revenue generating software platforms for the burgeoning capital raising industry created by the JOBS Act for medium sized issuer companies. Sprowtt Launch Pad Inc. plans to lead a robust federal lab-to-market campaign designed to stimulate technology transfer of U.S> government patanetdd inventions with strong market potential. This will be done through broad participation by leading colleges and universities and individual entrepreneurs, and focus on supporting commercialization of a wide-ranege of high-tech prodcust and services with technlgocal roots in the deferral government. The inititive will be enabled by the development and operation of Sprowtt’s Technlogy Transfer Gateway. The management team of Sprowtt Launch Pad has five decades of entrepreneurial experience, and has numerous years of experience successfully launching and managing more than a dozen early-stage ventures. The Sprowtt Launch Pad team has collectively raised several rounds of early stage capital and knows what it takes to launch a successful early stage company. The Sprowtt Launch Pad team has the experience to facilitate bringing together the right technology with the right entrepreneurs and partner them with the U.S. government technology transfer professionals to license the inteletual property. Sprowtt Lauch Pad is comitted to building successful early stage companies based on team relationships. Confidence and experience are important in bringing attractive and growing companies to our platform. All Americans now have the same opportunity to participate in Sprowtt Launch Pad through team building, with the right technologies available through governmentsponsored technology transfer programs.